Last Updated on December 31, 2023 by The Health Master
The U.S. Food and Drug Administration (USFDA) has approved Fennec Pharmaceuticals Inc’s intravenous therapy to prevent chemotherapy-induced hearing loss in children, according to the health regulator’s website.
The approval, posted on the regulator’s website late Tuesday, for Pedmark allows it to be used to reduce the risk of ototoxicity in children aged over one month who have undergone chemotherapy using the drug cisplatin.
Cisplatin is used in treating a range of cancers in children such as liver, bone and brain cancer, but can cause permanent hearing loss.
Pedmark is now the only approved therapy to prevent cisplatin-induced hearing loss in the United States, with most patients opting for either cochlear implants or hearing aids.
The company’s shares closed nearly 16% higher on Tuesday.
This was Fennec’s third attempt to secure approval for the intravenous treatment.
The FDA had twice declined to approve the therapy citing some deficiencies at the company’s manufacturing facility.
According to Fennec, nearly 10,000 children in the U.S. and Europe receive chemotherapy with cisplatin or similar drugs each year, and the incidence of hearing loss depends on the duration and dosage of the therapy.
USFDA approves Terlipressin for injection to treat Kidney function
USFDA gives tentative approval for Sugammadex Injection
USFDA gives approval for Lenalidomide capsules
USFDA gives final approval for Cariprazine capsules
USFDA gives approval for this cancer drug
USFDA approves Venlafaxine, Pregabalin extended release tablets
Panel asks Govt to bring essential Medical Devices under NLEM
Govt constitutes committee to regulate Pharma Marketing Practices
NPPA extends ceiling price fixation on orthopaedic Knee Implants
USFDA regulator resumes surprise inspections of pharma units in India
After raids in Pune, FDA cancels production license of Johnson and ohnson’s baby powder unit
USFDA issues Form 483 to Indoco with zero observation
NPPA fixes Retail Prices of 37 Formulations: September 2022
High Court: Marketing Companies will have a right to the Trademark
Drug alert: 45 out of 1330 samples declared as NSQ in August 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
